Gardasil

Types

Gardasil is available as Gardasil which protects against 4 types of HPV (6, 11, 16, 18) and Gardasil 9 which protects against an additional 5 types (31, 33, 45, 52, 58).

Medical uses

In the United States, Gardasil is indicated for:

• girls and women 9 through 45 years of age for the prevention of the following diseases:
  • Cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58.
  • Genital warts (condyloma acuminata) caused by HPV types 6 and 11.
• girls and women 9 through 45 years of age for the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58:
  • Cervical intraepithelial neoplasia (CIN) grade 2/3 and cervical adenocarcinoma in situ (AIS).
  • Cervical intraepithelial neoplasia (CIN) grade 1.
  • Vulvar intraepithelial neoplasia (VIN) grade 2 and grade 3.
  • Vaginal intraepithelial neoplasia (VaIN) grade 2 and grade 3.
  • Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3.
• boys and men 9 through 45 years of age for the prevention of the following diseases:
  • Anal, oropharyngeal and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
  • Genital warts (condyloma acuminata) caused by HPV types 6 and 11.
• boys and men 9 through 45 years of age for the following precancerous or dysplastic lesions caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58:
  • Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3.

In the European Union, Gardasil is indicated for active immunization of individuals from the age of nine years against the following HPV diseases:

• Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV types
• Genital warts (Condyloma acuminata) caused by specific HPV types.

Gardasil is a vaccine to prevent HPV, that, for maximum effect, is recommended for individuals prior to them becoming sexually active. Moreover, women who have already been infected with one or more of the four HPV types targeted by the vaccine (HPV types 6, 11, 16, or 18) may be protected from clinical disease caused by the remaining HPV types in the vaccine. HPV types 16 and 18 cause an estimated 70% of cervical cancers, and are responsible for most HPV-induced anal cancers. Gardasil also protects against vulvar and vaginal cancers caused by HPV types 16 and 18, as well as most penile cancers caused by these two HPV types.

In addition, protection against HPV types 6 and 11 may eliminate up to 90% of the cases of genital warts.—are not prevented by this vaccine.

In 2010, Gardasil was approved by the FDA for prevention of anal cancer and associated precancerous lesions due to HPV types 6, 11, 16, and 18 in people aged 9 through 26 years.

HPV infections, especially HPV 16, contribute to some head and neck cancer (HPV is found in an estimated 26–35% of head and neck squamous cell carcinoma). In principle, HPV vaccines may help reduce incidence of such cancers caused by HPV, but this has not been demonstrated. In June 2020, the FDA approved the use of Gardasil for the prevention of head and neck cancers.

The FDA approved Gardasil 9 for women and men aged 27 to 45 based on the vaccine being 88% effective against persistent HPV infections that cause certain types genital warts and cancers in females. Vaccine efficacy in males in this age group was inferred.

Efficacy

A 2020 longitudinal study tracking over 1.6 million Swedish girls and women over an eleven-year period found half as many cervical cancer cases in all women who had been vaccinated, and amongst women who had been vaccinated before the age of 17 a 78% reduction in cervical cancer, "a substantially reduced risk of invasive cervical cancer at the population level."

An alternative vaccine known as Cervarix protects against two oncogenic strains of HPV, 16 and 18.

The National Cancer Institute says, "To date, protection against the targeted HPV types has been found to last for at least 10 years with Gardasil, at least 9 years with Cervarix, and at least 6 years with Gardasil 9. Long-term studies of vaccine efficacy that are still in progress will help scientists better understand the total duration of protection."

Gardasil has been shown to be partially effective (approximately 38%) in preventing cervical cancer caused by ten other high-risk HPV types.

Antibody levels at month 3 (one month post-dose number two) are substantially higher than at month 24 (18 months post-dose number three), suggesting that protection is achieved by month 3 and perhaps earlier. In 2014, the World Health Organization (WHO) recommended that countries offer the vaccine in a two dose schedule to girls aged under 15, with each dose at least six months apart. The United Kingdom, Switzerland, Mexico, and Quebec province of Canada are among the countries or territories that have implemented this . The CDC recommended the vaccines be delivered in two shots over six months.

Males

Gardasil is also effective in males, providing protection against genital warts, anal warts, anal cancer, and some potentially precancerous lesions caused by some HPV types. Gardasil vaccine has been shown to decrease the risk of young men contracting genital warts. In the United States, the FDA approved administration of the Gardasil vaccine to males between ages 9 and 26 in 2009. The FDA approved administration of the Gardasil 9 vaccine to males between ages 9 and 15 in 2014, and extended the age indication, by including males between ages 16 and 26, in 2015. In the UK, HPV vaccines are licensed for males aged 9 to 15 and for females aged 9 to 26.

Men who have sex with men (MSM) are particularly at risk for conditions associated with HPV types 6, 11, 16, and 18; diseases and cancers that have a higher incidence among MSM include anal intraepithelial neoplasias, anal cancers, and genital warts. HPV type 16 is also responsible for almost 90% of HPV-positive oropharyngeal squamous-cell carcinoma (OPSCC), a form of cancer that affects the mouth, tonsils, and throat; the prevalence of HPV-positive oropharyngeal cancers is higher in males than females. A 2005 study found that 95% of HIV-infected gay men also had anal HPV infection, of whom 50% had precancerous HPV-caused lesions.

Administration

Gardasil is given in three injections over six months. The second injection is two months after the first, and the third injection is six months after the first shot was administered.

Adverse effects

, more than 170 million doses of Gardasil had been distributed worldwide. The vaccine was tested in thousands of females (ages 9 to 26). The US Food and Drug Administration (FDA) and the US Centers for Disease Control and Prevention (CDC) consider the vaccine to be safe. It does not contain mercury, thiomersal, live viruses or dead viruses, but virus-like particles, which cannot reproduce in the human body.

The vaccine has mostly minor side effects, such as pain around the injection area. General side effects of the shot may include joint and muscle pain, fatigue, physical weakness and general malaise.

The FDA and the CDC said that with millions of vaccinations "by chance alone some serious adverse effects and deaths" will occur in the time period following vaccination, but they have nothing to do with the vaccine. More than twenty women who received the Gardasil vaccine have died, but these deaths have not been causally connected to the shot, as correlation does not imply causation. Likewise, a small number of cases of Guillain–Barré syndrome (GBS) have been reported following vaccination with Gardasil, though there is no evidence linking GBS to the vaccine. It is unknown why a person develops GBS, or what initiates the disease.

The FDA and the CDC monitor events to see if there are patterns, or more serious events than would be expected from chance alone. In February 2009, the Spanish Ministry of Health suspended use of one batch of Gardasil after health authorities in the Valencia region reported that two girls had become ill after receiving the injection. Merck has stated that there was no evidence Gardasil was responsible for the two illnesses.

Ingredients

The following are the ingredients found in the different formulations of HPV vaccines:

• Major capsid protein L1 epitope of HPV types 6, 11, 16, and 18 (Gardasil)
• Major capsid protein L1 epitope of HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 (Gardasil-9)
• Major capsid protein L1 epitope of HPV types 16 and 18 (Cervarix)
• amorphous aluminum hydroxyphosphate sulfate (adjuvant)
• sodium chloride
• yeast protein
• L-histidine
• polysorbate 80
• sodium borate
• sodium dihydrogen phosphate dihydrate (Cervarix only)
• 3-O-Desacyl-4′-monophosphoryl lipid (MPL) A (Cervarix only)
• Aluminum hydroxide (Cervarix only)
• Trichoplusia ni insect cells (Cervarix only)

Biotechnology

The HPV major capsid protein, L1, can spontaneously self-assemble into virus-like particles (VLPs) that resemble authentic HPV virions. Gardasil contains recombinant VLPs assembled from the L1 proteins of HPV types 6, 11, 16 and 18. Since VLPs lack the viral DNA, they cannot induce cancer. They do, however, trigger an antibody response that protects vaccine recipients from becoming infected with the HPV types represented in the vaccine. The L1 proteins are produced by separate fermentations in recombinant Saccharomyces cerevisiae and self-assembled into VLPs.

Public health

Main article: HPV vaccines

The National Cancer Institute writes:

Long-term impact and cost-effectiveness

Whether the effects are temporary or lifelong, widespread vaccination could have a substantial public health impact. As of 2018, studies have proven that cervical cancer rates have dropped significantly since the introduction of Gardasil. Before Gardasil was introduced in 2006, 270,000 women died of cervical cancer worldwide in 2002. As of 2014, the mortality rate from cervical cancer has dropped 50% from 1975 which is due to the Gardasil vaccination along with increased focus on cervical screening. Acting FDA administrator Andrew von Eschenbach said the vaccine will have "a dramatic effect" on the health of women around the world. Gardasil is an important tool in reducing cervical cancer rates even in countries where screening programs are routine. The National Cancer Institute estimated that 9,700 women would develop cervical cancer in 2006, and 3,700 would die.

Merck and CSL Limited are expected to market Gardasil as a cancer vaccine, rather than an STD vaccine. In the early years of Gardasil's introduction it was unclear how widespread the use of the three-shot series would be, in part because of its $525 list price ($175 each for three shots). But as of 2013, vaccine coverage has been rising. In 2013, about 55% of girls ages 13–17 years had at least one dose of the vaccination covered, up from 29% in 2007. Coverage for women ages 18–34 also has increased significantly since 2007.

Studies using different pharmacoeconomic models predict that vaccinating young women with Gardasil in combination with screening programs may be more cost effective than screening alone. These results have been important in decisions by many countries to start vaccination programs. For example, the Canadian government approved $300 million to buy the HPV vaccine in 2008 after deciding from studies that the vaccine would be cost-effective especially by immunizing young women. Marc Steben, an investigator for the vaccine, wrote that the financial burden of HPV related cancers on the Canadian people was already $300 million per year in 2005, so the vaccine could reduce this burden and be cost-effective.

Since penile and anal cancers are much less common than cervical cancer, HPV vaccination of young men is likely to be much less cost-effective than for young women yet is still recommended due to the existent risk (including oral cancer).

The August 2009 issue of the Journal of the American Medical Association had an article reiterating the safety of Gardasil and another questioning the way it was presented to doctors and parents.

According to the CDC, as of 2012, use of the HPV vaccine had cut rates of infection with HPV-6, -11, -16 and -18 in half in American teenagers (from 11.5% to 4.3%) and by one third in American women in their early twenties (from 18.5% to 12.1%).

History

Research findings that pioneered the development of the vaccine began in 1991 by investigators Jian Zhou and Ian Frazer in the University of Queensland, Australia. Researchers at UQ found a way to form non-infectious virus-like particles (VLP), which could also strongly activate the immune system. Subsequently, the vaccine was developed in parallel by researchers at Georgetown University Medical Center in America, the University of Rochester in America, the University of Queensland in Australia, and the US National Cancer Institute. MedImmune, GSK, and Merck & Co. advanced these technologies and conducted clinical trials.

In December 2014, the FDA approved Gardasil 9, which protects against nine strains of HPV.

Society and culture

United States

A few conservative groups, such as the Family Research Council (FRC), have expressed their fears that vaccination with Gardasil might give girls a false sense of security regarding sex and lead to promiscuity, but no evidence exists to suggest that girls who were vaccinated went on to engage in more sexual activity than unvaccinated girls. Merck, the manufacturer of the vaccine, has lobbied that state governments make vaccination with Gardasil mandatory for school attendance, which has upset some conservative and libertarian groups.

The governor of Texas, Rick Perry, issued an executive order adding Gardasil to the state's required vaccination list, which was later overturned by the Texas legislature. Even though Perry also allowed parents to opt out of the program more easily, Perry's order was criticized, by fellow presidential candidates Rick Santorum and Michele Bachmann during the 2012 Republican Party presidential debate as being an overreach of state power in a decision properly left to parents.

Canada

Canada's National Advisory Committee on Immunization recommended HPV vaccination in 2007 for women and in 2012 for men. The Gardasil vaccine has been available free of charge to girls 12-17 in Canada since 2010.

Japan

In June 2013, the Japanese government issued a notice that "cervical cancer vaccinations should no longer be recommended for girls aged 12 to 16" while an investigation is conducted into certain adverse events including pain and numbness in 38 girls. The vaccines sold in Japan are Cervarix, made by GSK plc (formerly GlaxoSmithKline) of the United Kingdom, and Gardasil, made by Merck Sharp & Dohme. An estimated 3.28 million people have received the vaccination; 1,968 cases of possible side effects have been reported. In January 2014, the Vaccine Adverse Reactions Review Committee concluded that there was no evidence to suggest a causal association between the HPV vaccine and the reported adverse events, but did not reinstate proactive recommendations for its use. A study on girls in Sapporo showed that since the Japanese government's suspension of recommending the vaccine, completion rates for the full course of vaccination have dropped to 0.6%.

Australia

In 2021, Australian health authorities reported that for the first time in the 39 years that cervical cancer had been tracked, there were zero cases of cervical cancer in women under 25. Australia’s HPV vaccination program commenced in 2007.

References

References

1. (11 February 2019). "Human papillomavirus vaccine Use During Pregnancy".
2. (21 June 2022). "Prescription medicines: registration of new chemical entities in Australia, 2015".
3. (4 May 2016). "Health Canada New Drug Authorizations: 2015 Highlights".
4. (2 December 2020). "Gardasil- human papillomavirus quadrivalent- types 6, 11, 16, and 18 vaccine, recombinant injection, suspension".
5. (20 August 2021). "Gardasil 9- human papillomavirus 9-valent vaccine, recombinant injection, suspension".
6. (25 September 2009). "Silgard European Public Assessment Report". [[European Medicines Agency]].
7. (17 September 2018). "Silgard EPAR". [[European Medicines Agency]] (EMA).
8. (17 September 2018). "Gardasil 9 EPAR". [[European Medicines Agency]] (EMA).
9. (17 September 2018). "Gardasil EPAR". European Medicines Agency.
10. (2 October 2006). "International Approvals: Singulair and Gardasil/Silgard". Medscape Today.
11. (20 August 2009). "U.S. health officials back safety of Merck vaccine". Reuters.
12. (September 2013). "Gardasil administration to hr-HPV-positive women and their partners". Trends in Pharmacological Sciences.
13. "Genital HPV Infection - Fact Sheet". U.S. [[Centers for Disease Control and Prevention]] (CDC).
14. (March 2007). "Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR. Recommendations and Reports.
15. (May 2010). "FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)". MMWR. Morbidity and Mortality Weekly Report.
16. (May 2006). "Prophylactic human papillomavirus vaccines". The Journal of Clinical Investigation.
17. (August 2004). "Against which human papillomavirus types shall we vaccinate and screen? The international perspective". International Journal of Cancer.
18. (2016). "Human Papillomavirus and the Development of Different Cancers". Cytogenetic and Genome Research.
19. (May 2017). "Human papillomavirus vaccines: WHO position paper, May 2017". Weekly Epidemiological Record.
20. (4 December 2020). "Definitions". StatPearls Publishing.
21. "Human Papillomavirus (HPV) Vaccines".
22. (15 June 2017). "Gardasil". U.S. [[Food and Drug Administration]].
23. (8 June 2006). "FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus". U.S. [[Food and Drug Administration]] (FDA).
24. (April 2018). "Gardasil". Britannica Academic.
25. (January 2015). "Safety of quadrivalent human papillomavirus vaccine (Gardasil) in pregnancy: adverse events among non-manufacturer reports in the Vaccine Adverse Event Reporting System, 2006-2013". Vaccine.
26. (20 August 2009). "Gardasil Vaccine Safety". U.S. [[Food and Drug Administration]] (FDA).
27. (November 2011). "The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil". The Journal of Adolescent Health.
28. (10 October 2018). "Gardasil 9". U.S. [[Food and Drug Administration]] (FDA).
29. (10 December 2014). "FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV". U.S. [[Food and Drug Administration]] (FDA).
30. Research, Center for Biologics Evaluation and. (2025-03-26). "GARDASIL 9". FDA.
31. (September 2021 - March 2022). "British National Formulary (BNF)". BMJ Group and the Pharmaceutical Press.
32. (12 June 2020). "Gardasil 9". U.S. [[Food and Drug Administration]] (FDA).
33. (12 September 2008). "FDA Approves Expanded Uses for Gardasil to Include Preventing Certain Vulvar and Vaginal Cancers". U.S. [[Food and Drug Administration]] (FDA).
34. (February 2013). "Virus-like particles for the prevention of human papillomavirus-associated malignancies". Expert Review of Vaccines.
35. "Humanitas Papiloma Virus".
36. (22 December 2010). "FDA: Gardasil approved to prevent anal cancer". U.S. [[Food and Drug Administration]] (FDA).
37. (October 2009). "HPV & head and neck cancer: a descriptive update". Head & Neck Oncology.
38. (1994). "Viruses and Cancer". Press Syndicate of the University of Cambridge.
39. (11 May 2007). "Oral Sex Can Add to HPV Cancer Risk".
40. (12 June 2020). "FDA Approves Merck's Gardasil 9 for the Prevention of Certain HPV-Related Head and Neck Cancers".
41. (12 June 2020). "Gardasil Supplement Accelerated Approval". U.S. [[Food and Drug Administration]] (FDA).
42. (5 October 2018). "FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old". U.S. [[Food and Drug Administration]] (FDA).
43. (October 2020). "HPV Vaccination and the Risk of Invasive Cervical Cancer". The New England Journal of Medicine.
44. Centers for Disease Control Prevention. (May 2010). "FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)". MMWR. Morbidity and Mortality Weekly Report.
45. (November 2007). "HPV Vaccine Protects Against 10 "Other" Strains". Internal Medicine World Report.
46. (19 October 2016). "CDC recommends only two HPV shots for younger adolescents". U.S. [[Centers for Disease Control and Prevention]] (CDC).
47. (February 2011). "Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males". The New England Journal of Medicine.
48. (7 February 2011). "Gardasil safe and effective in young men". NAM aidsmap.
49. (23 February 2007). "Gay men seeking HPV vaccine". [[Cancer Research UK]].
50. (16 October 2009). "FDA Approves New Indication for Gardasil to Prevent Genital Warts in Men and Boys". U.S. [[Food and Drug Administration]] (FDA).
51. (16 October 2009). "October 16, 2009 Approval Letter – Gardasil". U.S. [[Food and Drug Administration]] (FDA).
52. (14 December 2015). "FDA licensure of 9-valent human papillomavirus vaccine to include males aged 16–26 years". [[Centers for Disease Control and Prevention.
53. (December 2015). "Provider Information: Gardasil 9 VIS". [[Centers for Disease Control and Prevention.
54. (14 December 2015). "Highlights of Prescribing InformationI: Gardasil 9". U.S. [[Food and Drug Administration]] (FDA).
55. (23 February 2007). "Gay men seek 'female cancer' jab". [[BBC News Online]].
56. (May 2007). "Case-control study of human papillomavirus and oropharyngeal cancer". The New England Journal of Medicine.
57. (29 August 2005). "HAART is not reducing risk of anal cancer in gay men". AIDSmap.
58. (24 January 2020). "Gardasil 9 suspension for injection - Summary of Product Characteristics (SmPC)".
59. (7 May 2019). "Gardasil suspension for injection - Summary of Product Characteristics (SmPC)".
60. (31 March 2014). "Expansion in Use of Cancer Vaccine".
61. "HPV Vaccine Information For Young Women". U.S. [[Centers for Disease Control and Prevention]] (CDC).
62. (9 February 2009). "Cervical cancer shots are gaining reputation as painful". [[ABC News (United States).
63. (10 July 2008). "Merck, FDA expand Gardasil warnings". [[The Washington Times]].
64. (19 August 2008). "Drug Makers' Push Leads to Cancer Vaccines' Fast Rise". [[The New York Times]].
65. (22 July 2008). "Information from FDA and CDC on Gardasil and its Safety (Archived)". U.S. [[Centers for Disease Control and Prevention]] (CDC).
66. (26 October 2010). "Reports of Health Concerns Following HPV Vaccination". U.S. [[Centers for Disease Control and Prevention]] (CDC).
67. (August 2009). "Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine". JAMA.
68. (18 July 2008). "HPV Vaccine – Questions & Answers for the Public".
69. (6 May 2010). "Guillain–Barré Syndrome Fact Sheet". National Institute of Neurological Disorders and Stroke (NINDS).
70. (18 August 2009). "HPV Vaccine: Debate Over Benefits, Marketing, and New Adverse Event Data". Medscape Today.
71. Castillo, Raquel. (10 February 2009). "Spain halts batch of Merck's Gardasil". Reuters.
72. (2015). "An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.". Pediatr Infect Dis J.
73. (July 2017). "HPV vaccines - A review of the first decade". Gynecologic Oncology.
74. "Gardasil Product Monograph". Merck Canada Inc..
75. (9 September 2019). "Human Papillomavirus (HPV) Vaccines". [[National Cancer Institute]] (NCI).
76. (9 August 2018). "Cervical cancer declines follow HPV vaccine introduction". AAP News.
77. (April 2005). "Public health. High hopes and dilemmas for a cervical cancer vaccine". Science.
78. (January 2018). "Cervical Cancer: Statistics".
79. (16 June 2006). "FDA approves first vaccine for cervical cancer". NBC News.
80. "SEER Stat Fact Sheets: Cervix Uteri". [[National Cancer Institute]].
81. "Health Blue Book".
82. (November 2007). "Prevention strategies against the human papillomavirus: the effectiveness of vaccination". Gynecologic Oncology.
83. (December 2007). "Human papilloma virus vaccine--more than a vaccine". Current Opinion in Obstetrics & Gynecology.
84. (2008). "The human papillomavirus vaccine in Canada". Canadian Journal of Public Health.
85. (March 2008). "Rebuttal: Do you approve of spending $300 million on HPV vaccination? Yes". Canadian Family Physician.
86. (August 2009). "Marketing HPV vaccine: implications for adolescent health and medical professionalism". JAMA.
87. (23 February 2016). "HPV Infection Rates Plummet In Young Women Due To Vaccine". Forbes.
88. (April 2006). "Who invented the VLP cervical cancer vaccines?". Journal of the National Cancer Institute.
89. (August 2006). "HPV vaccines: commercial research & development". Vaccine.
90. (11 December 2014). "FDA Approves Merck's HPV Vaccine, Gardasil 9, to Prevent Cancers and Other Diseases Caused by Nine HPV types – Including Types that Cause About 90% of Cervical Cancer Cases".
91. (21 February 2020). "Gardasil 9". U.S. [[Food and Drug Administration]] (FDA).
92. (14 September 2006). "Gardasil vaccine touted in Michigan". Spero News.
93. (2007). "Gardasil: What Parents should know about the new HPV vaccine". [[Family Research Council]].
94. (November 2012). "Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds". Pediatrics.
95. (21 February 2007). "Merck to halt lobbying for vaccine for girls". [[The New York Times]].
96. (26 March 2007). "Who's Afraid of Gardasil?". [[The Nation]].
97. (11 June 2006). "Moral majority take on GSK and Merck over cancer drugs". [[The Independent]].
98. (13 September 2011). "In Republican Race, a Heated Battle Over the HPV Vaccine". [[The New York Times]].
99. Lemay, Michel. (2022). "Intox: Journalisme d'enquête, désinformation et "cover-up"". Québec Amérique.
100. (16 June 2013). "Cervix vaccine issues trigger health notice". Japan Times.
101. (15 June 2013). "Health ministry withdraws recommendation for cervical cancer vaccine". The Asahi Shimbun.
102. (June 2015). "HPV vaccination crisis in Japan". Lancet.
103. (February 2022). "Japan resumes active recommendations of HPV vaccine after 8·5 years of suspension". Lancet Oncology.
104. "Australia on track to eliminating cervical cancer. But HPV vaccination and screening rates are falling". University of Sydney.